Loading candles…
Cohance Lifesciences Ltd., headquartered in Hyderabad, is a global technology-driven Contract Development and Manufacturing Organisation (CDMO) that delivers comprehensive solutions throughout a molecule's lifecycle. Operating in the pharmaceuticals, fine chemicals, and specialty chemicals industries, the company provides services including process research and development, early-stage development, late-stage clinical and commercial manufacturing, and large-scale commercialization. Cohance serves pharmaceutical and specialty chemical companies globally, supplying 19 of the top 20 global innovators and holding a top-three market share in eight of the ten primary active pharmaceutical ingredient (API) molecules. The company leverages specialized technology platforms in Antibody-Drug Conjugates (ADCs) and Oligonucleotides. Its business segments encompass Pharma CDMO, API+, and Specialty Chemicals. Cohance focuses on meeting customer requirements and expectations through its Hyderabad base. No details on founders, key management, subsidiaries, or stock exchange listings are provided.
This page is a live market overview for COHANCE LIFESCIENCES LTD (COHANCE) on the NSE. As a listed security, COHANCE LIFESCIENCES LTD is tracked in the Healthcare segment of the Indian cash market and is widely followed for price discovery, liquidity and sector exposure. Use this overview to review price action, session ranges and derivatives context for COHANCE before placing trades on tick2trade.
As of the latest feed, COHANCE last traded at ₹445.75 on NSE, up ₹6.85 (1.56%) from the previous close of ₹438.9. Today's session range is ₹432.85 – ₹449.2, against a 52-week band of ₹266.7 – ₹1,038.9. Traded volume today stands at 19.85L shares.
The overview consolidates an interactive price chart with multiple time ranges, recent market headlines, upcoming corporate events for COHANCE in one place so you do not need multiple screens during the session. Day and 52-week ranges help you judge whether COHANCE is trading near support, resistance or the middle of its recent band. Volume and depth, when available, add context on how aggressively the name is being bought or sold.
Equity overview pages are built for investors who want a single reference for COHANCE LIFESCIENCES LTD before reading news, checking results or sizing a position. Corporate events and headlines in the side column surface catalysts that may explain sudden moves in COHANCE. Related stocks in the same sector appear at the bottom of the page for quick peer comparison.
For a full option chain with greeks, open-interest bias, max pain and multi-leg strategy tools, open the tick2trade terminal or visit the dedicated COHANCE option chain page linked from this overview.
| Type | Details | Date |
|---|---|---|
| Results - FY26 | To consider and approve the financial results for the period ended Jun 30, 2026 | 5 Aug 2026 |
| Results - FY26 | To consider and approve the financial results for the period ended March 31, 2026 | 12 May 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended December 31, 2025 | 12 Feb 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended September 30, 2025 | 12 Nov 2025 |
| Unaudited Results - Q1-FY25 | To consider and approve the Unaudited Financial Results (Standalone and Consolidated) of the Company, for the quarter ending June 30, 2025 | 13 Aug 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended March 31, 2025 | 28 May 2025 |
Tick2trade is a brand/platform owned and operated by Besseggen InfoTech LLP, a SEBI Registered Stock Broker holding Registration No: INZ000213450, Member of NSE (Member Code: 90155) and BSE (Member Code: 6722). Investment in securities market are subject to market risks; read all related documents carefully before investing.